Colin Hislop Selected Research

varespladib methyl

2/2012	Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
12/2011	Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
4/2011	Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
10/2010	Varespladib methyl in cardiovascular disease.
9/2010	Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
2/2009	Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
1/2009	Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Colin Hislop Research Topics

Disease

5	Atherosclerosis 02/2012 - 01/2009
4	Acute Coronary Syndrome 02/2012 - 09/2010
3	Coronary Disease (Coronary Heart Disease) 04/2011 - 02/2009
2	COVID-19 01/2021 - 01/2021
1	Inflammation (Inflammations) 02/2012
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2010
1	Unstable Angina 09/2010
1	Myocardial Infarction 09/2010
1	Nausea 02/2009
1	Headache (Headaches) 02/2009
1	Chronic Obstructive Pulmonary Disease (COPD) 02/2009
1	Aneurysm (Aneurysms) 01/2009

Drug/Important Bio-Agent (IBA)

7	varespladib methylIBA 02/2012 - 01/2009
6	Secretory Phospholipases A2IBA 02/2012 - 01/2009
5	Phospholipases (Phospholipase)IBA 02/2012 - 02/2009
4	Biomarkers (Surrogate Marker)IBA 02/2012 - 02/2009
4	Lipoproteins (Lipoprotein)IBA 02/2012 - 02/2009
2	Atorvastatin (Lipitor)FDA Link 02/2012 - 09/2010
2	IsoenzymesIBA 04/2011 - 10/2010
2	Pharmaceutical PreparationsIBA 04/2011 - 02/2009
2	varespladibIBA 09/2010 - 01/2009
2	EnzymesIBA 02/2009 - 01/2009
1	peginterferon lambda-1aIBA 01/2021
1	Interferon LambdaIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Protein Isoforms (Isoforms)IBA 02/2012
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2011
1	C-Reactive ProteinIBA 09/2010
1	oxidized low density lipoproteinIBA 09/2010
1	LDL CholesterolIBA 09/2010
1	Apolipoproteins E (ApoE)IBA 01/2009
1	CholesterolIBA 01/2009
1	Angiotensin IIIBA 01/2009

Therapy/Procedure

4	Therapeutics 01/2021 - 09/2010
1	Subcutaneous Injections 01/2021